Longitudinal Evaluation Study of Vaginal Stenosis With and Without Pelvic Radiation Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01404728
Recruitment Status : Completed
First Posted : July 28, 2011
Last Update Posted : May 1, 2017
Information provided by (Responsible Party):
University of Colorado, Denver

Brief Summary:
This study evaluates the effects of treatment with a vaginal dilator to reduce vaginal stenosis in women receiving pelvic radiation therapy for pelvic malignancies.

Condition or disease
Malignancies Stenosis of Vagina

Detailed Description:
Vaginal stenosis can occur as a result of treatment for pelvic malignancies. Women receiving pelvic radiation therapy using a vaginal dilator 5-7 times per week will have less vaginal stenosis than women using a vaginal dilator fewer times or not at all.

Study Type : Observational
Actual Enrollment : 8 participants
Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: Prospective Longitudinal Evaluation of Vaginal Stenosis and Sexual Function in Women With Pelvic Malignancies Treated With and Without Pelvic Radiation Therapy
Actual Study Start Date : January 8, 2013
Actual Primary Completion Date : January 22, 2013
Actual Study Completion Date : March 1, 2017

Pelvic Malignancies
Women with Vaginal Stenosis

Primary Outcome Measures :
  1. Observation of a change in vaginal length as measured with a vaginal sound (modified vaginal dilator) [ Time Frame: Up to 24 Months ]
    Observation of change in vaginal length will be measured at baseline (which for the patients in the radiation group will be prior to any pelvic radiation therapy and for patients in the surgery group this will be at the first post-operative visit), as well as in follow-up visits at 3, 6, 12, and 24 months for a total of 5 measurements.

  2. Observation of change in sexual function/satisfaction as measured by the Sexual Adjustment Questionnaire (SAQ) [ Time Frame: Up to 24 Months ]
    The baseline SAQ will be administered prior to radiation therapy for the pelvic malignancy group and it will be administered at the post-operative visit for the surgery only group, and the post-treatment SAQ version will be given at the follow-up visits at 3, 6, 12, and 24 months for a total of 5 measurements.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Women being treated for pelvic malignancies in the primary care clinic.

Inclusion Criteria:

  • Pre and post menopausal women undergoing definitive (not palliative) treatments for a pelvic malignancy, including rectal, endometrial, cervical, or anal canal carcinoma.
  • Treatments include radiation therapy, chemotherapy, surgery, or a combination of therapies.
  • May have early-stage or locally advanced (node positive) disease.
  • Male partners of the female subjects are also consented for this study.

Exclusion Criteria:

  • Subject may not have evidence of metastatic disease.
  • Prior pelvic radiation therapy
  • Prior hysterectomy (not for current diagnosis)
  • Diagnosis of prior malignancy, except non-melanoma skin cancer.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01404728

United States, Colorado
University of Colorado Hospital
Aurora, Colorado, United States, 80045
Sponsors and Collaborators
University of Colorado, Denver
Principal Investigator: Christine Fisher, MD University of Colorado, Denver

Responsible Party: University of Colorado, Denver Identifier: NCT01404728     History of Changes
Other Study ID Numbers:
First Posted: July 28, 2011    Key Record Dates
Last Update Posted: May 1, 2017
Last Verified: April 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by University of Colorado, Denver:
Vaginal length
Sexual dysfunction

Additional relevant MeSH terms:
Constriction, Pathologic
Pathological Conditions, Anatomical